Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma

Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma

IntroductionPoint-of-care (POC) manufacturing of chimeric antigen receptor (CAR) modified T cell has expanded rapidly over the last decade. In addition to the use of CD19 CAR T cells for hematological diseases, there is a growing interest in targeting a variety of tumor-associated epitopes.MethodsHe...

Full description

Saved in:
Bibliographic Details
Main Authors: Krasimira Aleksandrova, Jana Leise, Christoph Priesner, Murat Aktas, Michael Apel, Mario Assenmacher, Iris Bürger, Anne Richter, Pia Altefrohne, Christine Schubert, Astrid Holzinger, Markus Barden, Valerie Bezler, Michael von Bergwelt-Baildon, Peter Borchmann, Lilia Goudeva, Wolfgang Glienke, Lubomir Arseniev, Ruth Esser, Hinrich Abken, Ulrike Koehl
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-09-01
Series:Frontiers in Immunology
Subjects:
clinical CD20 CAR T cell trial
automated manufacturing of engineered T cell products
ex vivo expansion
cell composition of CAR T cell products
CD20 CAR investigational medicinal product
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1328368/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1328368/full

Similar Items